Teva will invest in OTC as ‘core asset’ for group
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Teva’s OTC portfolio remains a “core asset” in which the Israeli generics giant will continue to invest, according to chief executive officer Kåre Schultz.